Next Generation Sequencing

Hands-on training in the latest next generation sequencing systems. 1 April, 2022 - 8 April, 2022

Wellcome Genome Campus, UK

Web Address

General Information

Next generation sequencing has become the premier tool in genetic and genomic analysis.  This lab course is directed at scientists who will be generating and interpreting sequence information in their research and wish to gain a better understanding of the platforms and techniques involved, and their applications.

The programme will include theoretical and practical information on next-generation sequencing systems currently available and those on the near horizon.  Technologies will be chosen from short- and long-read sequencing platforms including,

  • PacBio
  • Illumina Miseq/HiSeq
  • Oxford Nanopore MinION

A key aim of the course is to allow participants to make informed decisions about which technology to apply to solve specific research questions they may face in the future.  A variety of applications will be covered, e.g.,

  • target enrichment
  • bacterial sequencing
  • cancer genomics
  • human variation analysis
  • RNA-Seq

All the basic techniques of post-sequencing analysis will also be covered in hands-on sessions (QC, alignment, assembly, variant calling, etc.)

Please note: For the data analysis components of the course, applicants will require a working knowledge of the UNIX/Linux operating system.  This can be obtained by various methods and is essential to fully benefit from the course.  There are numerous online introductory tutorials to the UNIX/Linux operating system and command line, including:

This course is not meant to replace the manufacturers’ training normally supplied with new instruments, nor is it intended to be a training course for those solely interested in next generation sequencing data analysis (please refer to our website for dedicated bioinformatics courses).

Meeting organisers:

Wellcome Connecting Science Courses


Instructors: Louise Aigrain (Wellcome Sanger Institute, UK), Jacqueline Keane (Wellcome Sanger Institute, UK) and Michael Quail (Wellcome Sanger Institute, UK).